Literature DB >> 32067369

Worldwide implementation of clinical services for the prevention of psychosis: The IEPA early intervention in mental health survey.

Magdalena Kotlicka-Antczak1, Michał Podgórski2, Dominic Oliver3, Nadja P Maric4, Lucia Valmaggia5,6, Paolo Fusar-Poli3,7,8,6.   

Abstract

BACKGROUND: Clinical research into the Clinical High Risk state for Psychosis (CHR-P) has allowed primary indicated prevention in psychiatry to improve outcomes of psychotic disorders. The strategic component of this approach is the implementation of clinical services to detect and take care of CHR-P individuals, which are recommended by several guidelines. The actual level of implementation of CHR-P services worldwide is not completely clear. AIM: To assess the global geographical distribution, core characteristics relating to the level of implementation of CHR-P services; to overview of the main barriers that limit their implementation at scale.
METHODS: CHR-P services worldwide were invited to complete an online survey. The survey addressed the geographical distribution, general implementation characteristics and implementation barriers.
RESULTS: The survey was completed by 47 CHR-P services offering care to 22 248 CHR-P individuals: Western Europe (51.1%), North America (17.0%), East Asia (17.0%), Australia (6.4%), South America (6.4%) and Africa (2.1%). Their implementation characteristics included heterogeneous clinical settings, assessment instruments and length of care offered. Most CHR-P patients were recruited through mental or physical health services. Preventive interventions included clinical monitoring and crisis management (80.1%), supportive therapy (70.2%) or structured psychotherapy (61.7%), in combination with pharmacological treatment (in 74.5%). Core implementation barriers were staffing and financial constraints, and the recruitment of CHR-P individuals. The dynamic map of CHR-P services has been implemented on the IEPA website: https://iepa.org.au/list-a-service/.
CONCLUSIONS: Worldwide primary indicated prevention of psychosis in CHR-P individuals is possible, but the implementation of CHR-P services is heterogeneous and constrained by pragmatic challenges.
© 2020 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  clinical high risk; early intervention; implementation; psychosis; schizophrenia

Mesh:

Year:  2020        PMID: 32067369     DOI: 10.1111/eip.12950

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  20 in total

Review 1.  Mental Health Services Research Targeting the Clinical High-Risk State for Psychosis: Lessons, Future Directions and Integration with Patient Perspectives.

Authors:  Sarah V McIlwaine; Jai Shah
Journal:  Curr Psychiatry Rep       Date:  2021-02-03       Impact factor: 5.285

2.  Equity in Mental Health Services for Youth at Clinical High Risk for Psychosis: Considering Marginalized Identities and Stressors.

Authors:  Joseph S DeLuca; Derek M Novacek; Laura H Adery; Shaynna N Herrera; Yulia Landa; Cheryl M Corcoran; Elaine F Walker
Journal:  Evid Based Pract Child Adolesc Ment Health       Date:  2022-03-23

3.  Potential for prediction of psychosis and bipolar disorder in Child and Adolescent Mental Health Services: a longitudinal register study of all people born in Finland in 1987.

Authors:  Ulla Lång; Hugh Ramsay; Kathryn Yates; Juha Veijola; David Gyllenberg; Mary C Clarke; Finbarr P Leacy; Mika Gissler; Ian Kelleher
Journal:  World Psychiatry       Date:  2022-10       Impact factor: 79.683

4.  The lived experience of psychosis: a bottom-up review co-written by experts by experience and academics.

Authors:  Paolo Fusar-Poli; Andrés Estradé; Giovanni Stanghellini; Jemma Venables; Juliana Onwumere; Guilherme Messas; Lorenzo Gilardi; Barnaby Nelson; Vikram Patel; Ilaria Bonoldi; Massimiliano Aragona; Ana Cabrera; Joseba Rico; Arif Hoque; Jummy Otaiku; Nicholas Hunter; Melissa G Tamelini; Luca F Maschião; Mariana Cardoso Puchivailo; Valter L Piedade; Péter Kéri; Lily Kpodo; Charlene Sunkel; Jianan Bao; David Shiers; Elizabeth Kuipers; Celso Arango; Mario Maj
Journal:  World Psychiatry       Date:  2022-06       Impact factor: 79.683

5.  Preventive psychiatry: a blueprint for improving the mental health of young people.

Authors:  Paolo Fusar-Poli; Christoph U Correll; Celso Arango; Michael Berk; Vikram Patel; John P A Ioannidis
Journal:  World Psychiatry       Date:  2021-06       Impact factor: 79.683

6.  Antipsychotics are related to psychometric conversion to psychosis in ultra-high-risk youth.

Authors:  Antonio Preti; Andrea Raballo; Anna Meneghelli; Angelo Cocchi; Maria Meliante; Simona Barbera; Lara Malvini; Emiliano Monzani; Mauro Percudani
Journal:  Early Interv Psychiatry       Date:  2021-05-05       Impact factor: 2.721

7.  Real-world long-term outcomes in individuals at clinical risk for psychosis: The case for extending duration of care.

Authors:  Paolo Fusar-Poli; Andrea De Micheli; Lorenzo Signorini; Helen Baldwin; Gonzalo Salazar de Pablo; Philip McGuire
Journal:  EClinicalMedicine       Date:  2020-10-07

8.  A qualitative study on identity in individuals at clinical high risk for psychosis: " … Why does it have to be one thing?".

Authors:  Cansu Sarac; Joseph S DeLuca; Zarina R Bilgrami; Shaynna N Herrera; Jonathan J Myers; Matthew F Dobbs; Shalaila S Haas; Therese L Todd; Agrima Srivastava; Rachel Jespersen; Riaz B Shaik; Yulia Landa; Larry Davidson; Anthony J Pavlo; Cheryl M Corcoran
Journal:  Psychiatr Rehabil J       Date:  2021-06-17

9.  Risk factors for eating disorders: an umbrella review of published meta-analyses.

Authors:  Marco Solmi; Joaquim Radua; Brendon Stubbs; Valdo Ricca; Davide Moretti; Daniele Busatta; Andre F Carvalho; Elena Dragioti; Angela Favaro; Alessio Maria Monteleone; Jae Il Shin; Paolo Fusar-Poli; Giovanni Castellini
Journal:  Braz J Psychiatry       Date:  2020-09-28       Impact factor: 2.697

10.  New Electronic Health Records Screening Tools to Improve Detection of Emerging Psychosis.

Authors:  Paolo Fusar-Poli
Journal:  Front Psychiatry       Date:  2021-07-14       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.